Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Erleada
Pharma
J&J's Erleada shows survival edge over Xtandi in real-world study
A real-world, head-to-head study of prostate cancer drugs indicates that J&J’s Erleada provides an edge in overall survival versus Xtandi.
Kevin Dunleavy
Oct 2, 2024 2:42pm
J&J touts progress on new launches as Stelara cliff nears
Oct 17, 2023 10:15am
J&J breaks out the blue jacket for prostate cancer awareness
Feb 7, 2023 7:35am
J&J kicks off prostate cancer health disparities campaign
Sep 21, 2022 9:25am
Bayer's Nubeqa nabbed a second prostate cancer indication
Aug 8, 2022 10:13am
Bayer wins priority review for prostate cancer drug Nubeqa
May 3, 2022 3:37pm
